Results of the CONFIRM study presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium reveals that doubling the dose of fulvestrant to 500mg from 250mg can improve the overall survival chances in women who suffer from advanced or metastatic estrogen receptor-positive breast cancer. The Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) trial is a randomized, double-blind, parallel-group, multicenter, phase III trial of postmenopausal ...
via Medindia Health News
More READ
No comments:
Post a Comment